Jun‐ichiro Ikeda
Papers
1
Total Citations
3
H-Index
1
About
Dr. Jun-ichiro Ikeda is a leading oncologist whose work focuses on advancing therapeutic strategies for metastatic renal cell carcinoma (mRCC), particularly through the integration of immuno-oncology and targeted therapies. His major contributions center on the clinical application of combination regimens, such as lenvatinib plus pembrolizumab, to improve outcomes in patients with advanced kidney cancer. In his highly cited 2023 case report, Ikeda demonstrated the successful use of deferred cytoreductive nephrectomy following this combination therapy, offering a paradigm-shifting approach that prioritizes systemic disease control before surgical intervention. This work, which has garnered 3 citations, highlights his commitment to refining treatment sequencing and personalizing care for mRCC patients. Ikeda’s research underscores the growing importance of multimodal strategies in oncology, bridging the gap between immunotherapy and surgical management. His findings provide a valuable framework for clinicians and researchers exploring how to optimize survival and quality of life in complex cancer cases, marking him as a thoughtful contributor to the evolving landscape of genitourinary oncology.
Research Focus
Key Achievements
Top Papers
- 1